(Q37008618)

17 August 2017

1 reference

title

Antiangiogenic agents in breast cancer (English)

1 reference

17 August 2017

main subject

angiogenesis inhibitor

1 reference

1 reference

2

Kathy D Miller

1 reference

17 August 2017

John T Salter

1

1 reference

17 August 2017

publication date

1 October 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

25

1 reference

17 August 2017

issue

7

1 reference

17 August 2017

page(s)

518-526

1 reference

Vascular-specific growth factors and blood vessel formation

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

The implications of angiogenesis for the biology and therapy of cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Angiogenesis: A Marker for Neoplastic Transformation of Mammary Papillary Hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Clinical translation of angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Metronomic scheduling: the future of chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Redefining the target: chemotherapeutics as antiangiogenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Development of matrix metalloproteinase inhibitors in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Anti-angiogenic therapy: rationale, challenges and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Medical imaging techniques in the evaluation of strategies for therapeutic angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Molecular imaging of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Maximizing the potential of bevacizumab in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Angiogenesis of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Correlation of Vascular Endothelial Growth Factor Content With Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701648516

10.1080/07357900701648516

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference